The U.S. Food and Drug Administration to use IPA in review of Pharmacogenomics Submissions


Mountain View, CA – June 21, 2005 – Ingenuity announced today that the U.S. Food and Drug Administration (FDA) have licensed IPA for use in the review of pharmacogenomics data submissions. The FDA and Ingenuity will work together to link IPA with ArrayTrack using the newly available IPA Integration Module.

The IPA application enables scientists to simultaneously analyze multiple genomic and proteomic datasets to rapidly gain biological insights. ArrayTrack, a microarray data management, analysis and interpretation system was developed by the Center for Toxicoinformatics at the National Center for Toxicological Research (NCTR) of the FDA, and is a module of a comprehensive software system, the Toxicoinformatics Integrated System.

“The integration of ArrayTrack and IPA provides the FDA scientists with a next generation capability for the analysis of pharmacogenomic data submissions and should permit the FDA reviewers to be more comprehensive and efficient in reviewing drug efficacy and safety,” stated Jake Leschly, Chief Executive Officer at Ingenuity.

Scientists use IPA in all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and patient stratification. The easy to use application makes use of the Ingenuity Pathways Knowledge Base, the world’s largest curated database consisting of millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases. IPA is available as a web-delivered, hosted, or deployed solution and fully functional complimentary trials are available to qualified scientists at

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,